Mayne Pharma Group Limited Appoints Shawn Patrick O'Brien
as Chief Executive Officer and Managing Director

28 September 2022, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce it has appointed Mr. Shawn Patrick O’Brien as Chief Executive Officer (CEO) and Managing Director effective from 1 October 2022. This follows from the previously announced retirement of Mr Scott Richards and a comprehensive search for a successor.

Mr O’Brien has more than 35 years of global pharmaceutical industry experience building successful enterprises. He is currently founding partner of Key BioPharma Partners providing advice to life science companies and capital providers. He was previously the Chairman and CEO of Genomind Inc., a personalised mental health platform company, and CEO of publicly listed Cipher Pharmaceuticals Inc., a specialty pharmaceutical company with a portfolio of commercial stage dermatology products. He has also been President and CEO of three private biotechs including AltheRx Pharmaceuticals; Profectus BioSciences and Solstice Neurosciences. Mr O’Brien held multiple senior leadership roles at AstraZeneca, one of the largest global pharmaceutical companies. At AstraZeneca he was responsible for key brands such as FASLODEX®, SYMBICORT®, PULMICORT® and SEROQUEL® which all became billion-dollar brands. More.

Convergent Therapeutics Appoints
Alexander Brown as Chief Operating Officer

Biopharmaceutical Industry Veteran Brings
Key Commercial and Operational Expertise

CAMBRIDGE, Mass., Aug. 30, 2021 /PRNewswire/ -- Convergent Therapeutics, a clinical stage pharmaceutical company focused on developing next generation radiopharmaceutical therapies for prostate and other cancers, today announced the appointment of Alexander Brown to the newly created position of Chief Operating Officer.

"Alex brings to Convergent extensive commercial and operational expertise, gained from his experience with a number of the industry's top biopharmaceutical companies including Sanofi, Pfizer, Merck KGaA and others," stated Philip Kantoff, M.D., Chief Executive Officer of Convergent Therapeutics. "We are eager to leverage Alex's exceptional talents at this critical juncture, as we continue to build out our team and progress our unique pipeline of next generation radio-pharmaceutical therapies, initially aimed at prostate cancer." More.

The Camille and Henry Dreyfus Foundation welcomes
Dr. Scott A. Siegel as their new Executive Director

Scott Siegel has spent more than 35 years as a scientific and business leader. Prior to joining the Foundation, Dr. Siegel was VP & Chief Business Officer for ATCC, a non-profit in the life sciences. He founded Milestone Life Sciences, a strategic advisory and partnering firm, and previously held senior leadership roles in public and private companies ranging from start-up to multinational, including COO at Ezose Sciences, VP at Redpoint Bio, and Executive Director at Johnson & Johnson. Dr. Siegel also served as VP for the non-profit Institute for Life Science Entrepreneurship. He has broad international experience, facilitating partnerships across North America, Europe and Asia. More.

Ocugen Appoints Sanjay S. Subramanian, MBA,
as Chief Financial Officer

MALVERN, Pa., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced the appointment of Sanjay S. Subramanian, MBA, to the role of Chief Financial Officer, effective October 1, 2019. More.

BlueSphere Bio Names Veteran Biotech Leader David Apelian
as CEO - with Pitt Expertise and UPMC Funding, BlueSphere's
TCXpress Platform to Develop Rapid, Personalized T-Cell
Therapies for Cancer Treatment - 7/31/2019

PITTSBURGH -- BlueSphere Bio, an immunotherapy startup formed by UPMC Enterprises and focused on creating personalized therapies for cancer, announced today that David Apelian, M.D., Ph.D., M.B.A., has been named chief executive officer of the company. He joins top clinical immunology experts and company co-founders Mark Shlomchik, M.D., Ph.D., and Warren Shlomchik, M.D., of the University of Pittsburgh to advance the TCXpress platform to develop rapid, personalized T-cell therapies for cancer. More.

Agilvax, Inc. Appoints Joseph Patti, Ph.D.
as Executive Chairman

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Agilvax, Inc. a biotechnology company developing targeted antibody-based therapeutics for the treatment of various types of cancers announced today that Joseph Patti, Ph.D., will join its Board of Directors as Executive Chairman. More.

Advaxis, Inc. announces the Appointment of Andres A. Gutierrez
as Executive Vice President, Chief Medical Officer

PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced Andres A. Gutierrez, M.D., Ph.D. has been named Executive Vice President, Chief Medical Officer, effective April 23, 2018. More.

SELLAS Life Sciences Announces Appointment of Gene Mack
as Chief Financial Officer & Treasurer

NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a clinical-stage biopharmaceutical company focused on novel cancer immunotherapies for a broad range of cancer indications, today announced the appointment of Gene Mack as Chief Financial Officer and Treasurer. More.

Pacira Pharmaceuticals, Inc. announces the Appointments of
Thomas Sluby as Vice President, Sales and Matthew Lehmann
as Vice President, Marketing – Emerging Therapies

PARSIPPANY, N.J., Oct. 20, 2016 - Pacira Pharmaceuticals, Inc. (PCRX) today announced the appointment of two key individuals who will assume leadership roles within the company’s commercial organization. Thomas Sluby has been named Vice President, Sales and Matthew Lehmann has been appointed Vice President, Marketing – Emerging Therapies; both individuals will report to Robert Weiland, Chief Commercial Officer. More.

Noxilizer announces David A. Theil,
Senior Vice President And CFO

Experienced Life Science Financial Executive Joins Management Team
January 26, 2016 (Baltimore, MD) Noxilizer, Inc., the company advancing a room temperature, NO2-based sterilization and decontamination process for bio-pharmaceutical and medical device manufacturers announces David A. Theil as their new Senior Vice President and Chief Financial Officer (CFO). More.

BD announces Appointment of Dr. Ellen Strahlman
as Chief Medical Officer and Senior Vice President,
Research & Development

Franklin Lakes, NJ (March 13, 2013) – BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Ellen Strahlman, M.D., M.H.Sc., to the newly created position of Chief Medical Officer and Senior Vice President, Research & Development, effective April 22, 2013. Dr. Strahlman will report to Chairman, CEO and President Vincent A. Forlenza and will serve as a member of the Company’s Management Committee and Leadership Team. In her new role, Dr. Strahlman will oversee the Company’s Medical Affairs and Research & Development functions. More.